Paul Terence Kohler, Jr. is the Chief Financial Officer and Treasurer of ADMA Biologics, Inc., a fully integrated commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics derived from human plasma for the treatment of immune deficiencies and infectious diseases. Since joining ADMA in October 2020, Kohler has played a pivotal role in strengthening the company's financial infrastructure, overseeing all aspects of financial planning, reporting, treasury operations, investor relations, and capital markets activities. His leadership has been instrumental in supporting ADMA's growth, including key financings and the commercialization of its flagship product, ASCENIV. With over 25 years of experience in the life sciences and healthcare sectors, Kohler brings a proven track record of guiding public companies through complex financial landscapes. Prior to ADMA, he served as Senior Vice President of Finance and Administration and Chief Financial Officer at Kura Oncology, Inc. from 2018 to 2020, where he managed financial operations for the clinical-stage oncology company. Previously, he was Vice President of Finance and Principal Accounting Officer at Puma Biotechnology, Inc. from 2016 to 2018, contributing to the company's initial public offering and subsequent equity financings raising over $500 million. Earlier roles include senior finance positions at Orexigen Therapeutics, Inc. and as an audit manager at Deloitte & Touche LLP. Kohler's achievements include successfully navigating multiple SEC filings, debt and equity offerings, and operational turnarounds in dynamic biotech environments. A Certified Public Accountant in California, he holds a Bachelor of Science in Accounting from the University of San Diego and an MBA from San Diego State University, equipping him with deep expertise in strategic financial management that continues to drive ADMA Biologics' path toward sustainable profitability and innovation.